Previous 10 | Next 10 |
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most part...
New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from...
2024-03-02 04:53:00 ET On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen , (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newl...
2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...
2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...
2024-02-23 07:59:52 ET More on Biogen Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen Inc. 2023 Q4 - Results - Earnings Call Presentation DOJ issues subpoena for info on...
SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the...
2024-02-21 14:33:22 ET More on Invesco QQQ ETF QQQ: Why It Could Be The Best Single Investment For The Next 20+ Years SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat Mean Reversion Pair Trade: Long IWM, Shor...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.8% to $11.65 on volume of 139,655,455 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.1% to $4.39 on volume of 127,826,661 shares SoundHound AI Inc. (SOUN) rose 1.6% to $3.82 on volume of...
2024-02-17 03:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...